Beigene
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry.
The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
+5 vs industry average
Beigene’s score of 43 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Beigene?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Beigene's reported carbon emissions
In 2025, BeiGene reported total carbon emissions of approximately 745,000,000 kg CO2e, comprising 11,539,000 kg CO2e from Scope 1, 102,622,000 kg CO2e from Scope 2, and 627,386,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, BeiGene targets a 30% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Furthermore, they plan to achieve a 25% reduction in Scope 1 and 2 emissions per unit of internally manufactured commercial products by 2026, with 2021 as the baseline. These initiatives demonstrate BeiGene's commitment to sustainability and align with industry standards for climate action. The emissions data and reduction targets are sourced directly from BeiGene, Ltd., ensuring accuracy and relevance in their climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Beigene’s Climate Goals (2030 & 2050)
6 goals2030
30% reduction in Scope 1
We aim to achieve a 30% reduction in our Scope 1 emissions by 2030 from a 2020 baseline.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 6 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Beigene
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project